≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Chloasma

DOID EFO Endpoint Browser PheWeb

L12_CHLOASMA

obsolete_incontinentia pigmenti achromians: a dermal melanocytic condition affecting the shoulder area. Nevus of Ito often occurs in association with nevus of Ota in the same patient but is much less common, although the true incidence is unknown.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — L81.1
  • Hospital discharge: ICD-9 — 7090A
  • Hospital discharge: ICD-8 — 7090[0-2]
  • Cause of death: ICD-10 — L81.1
  • Cause of death: ICD-9 — 7090A
  • Cause of death: ICD-8 — 7090[0-2]

2 out of 7 registries used, show all original rules.

201

4. Check minimum number of events

None

201

5. Include endpoints

None

201

6. Filter based on genotype QC (FinnGen only)

182

Control definitions (FinnGen only)

Control exclude
L12_OTHERSKINSUBCUTIS

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
L81
Name in latin
Chloasma

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 918 754 148
Only index persons 851 720 131
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.00
Only index persons 0.02 0.03 0.01
Median age at first event (years)
Whole population 47.29 48.22 43.92
Only index persons 47.24 48.03 42.87

-FinnGen-

Key figures

All Female Male
Number of individuals 182 157 25
Unadjusted period prevalence (%) 0.05 0.06 0.01
Median age at first event (years) 52.32 52.84 49.10

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
201
Matched controls
2010
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L81.1
ICD-10 Finland
Chloasma
+∞
243.3
181
*
L57.0
ICD-10 Finland
Actinic keratosis
4.4
14.5
42
114
L82
ICD-10 Finland
Seborrhoeic keratosis
3.5
14.2
63
231
L81.4
ICD-10 Finland
Other melanin hyperpigmentation
63.5
10.7
12
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.0
9.2
28
78
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.4
8.0
73
380
7090A
ICD-9 Finland
Other disorders of skin and subcutaneous tissue, Dyschromia[CHLOASMA]
+∞
7.3
7
*
QAA05
NOMESCO Finland
Incision for biopsy of skin of head or neck
12.8
6.7
11
9
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
3.5
6.5
24
76
D10AX03
ATC
azelaic acid; topical
3.2
6.5
28
98
Z01.8
ICD-10 Finland
Other specified special examinations
2.3
6.5
59
303
70901
ICD-8 Finland
Other diseases of skin, Chloasma symptomaticum aliud sive NUD
+∞
6.3
6
*
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.1
6.3
91
564
S08
ICPC
Skin colour change
3.8
6.0
19
54

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
1.3e+00
2.2e+00
2.6e+00
—
2.9e+00
3.0e+00
1.9e+00
cases:19.25%
controls:5.99%
cases:16.04%
controls:2.14%
cases:4.81%
controls:0.37%
—
—
cases:8.02%
controls:0.48%
cases:26.79%
controls:1.83%
cases:27.66%
controls:5.19%
36
112
151
1758
30
40
157
1830
9
7
178
1863
—
15
9
172
1851
45
31
123
1665
39
70
102
1278
Actinic keratosis
L57.0 [45591640]
1.2e+00
2.5e+00
—
1.0e+50
—
2.9e+00
1.9e+00
cases:4.81%
controls:1.44%
cases:5.88%
controls:0.53%
—
—
cases:3.21%
controls:0.00%
—
—
cases:5.95%
controls:0.35%
cases:7.80%
controls:1.19%
9
27
178
1843
11
10
176
1860
—
6
0
181
1870
—
10
6
158
1690
11
16
130
1332
tretinoin; ointment
D10AD01 [21602293]
2.5e+00
—
—
1.0e+50
—
—
2.1e+00
cases:3.74%
controls:0.32%
—
—
—
—
cases:4.81%
controls:0.00%
—
—
—
—
cases:5.67%
controls:0.74%
7
6
180
1864
—
—
9
0
178
1870
—
—
8
10
133
1338
Supplier / Service Provider
OMOP5117446 [33004]
-1.0e+00
-8.4e-01
-1.0e+50
—
—
2.5e+00
2.7e+00
cases:14.44%
controls:31.60%
cases:3.21%
controls:7.11%
cases:0.00%
controls:0.53%
—
—
—
—
cases:4.17%
controls:0.35%
cases:10.64%
controls:0.82%
27
591
160
1279
6
133
181
1737
0
10
187
1860
—
—
7
6
161
1690
15
11
126
1337
Case Management Agency
251B00000X [38004193]
1.2e-01
1.8e-01
1.9e-01
3.9e+00
4.9e-01
8.7e-02
3.0e-01
cases:64.17%
controls:61.34%
cases:60.96%
controls:56.52%
cases:28.88%
controls:25.19%
cases:42.78%
controls:1.44%
cases:34.22%
controls:24.19%
cases:57.14%
controls:55.01%
cases:74.47%
controls:68.32%
120
1147
67
723
114
1057
73
813
54
471
133
1399
80
27
107
1843
64
450
123
1410
96
933
72
763
105
921
36
427
Seborrhoeic keratosis
L82 [45548208]
1.4e+00
1.3e+00
—
1.0e+50
—
1.6e+00
1.8e+00
cases:7.49%
controls:1.87%
cases:3.21%
controls:0.91%
—
—
cases:8.56%
controls:0.00%
—
—
cases:2.98%
controls:0.59%
cases:8.51%
controls:1.48%
14
35
173
1835
6
17
181
1853
—
16
0
171
1870
—
5
10
163
1686
12
20
129
1328
Outpatient Visit
OP [9202]
6.2e-01
7.4e-01
5.0e-01
—
9.4e-01
7.3e-01
7.8e-01
cases:82.89%
controls:72.19%
cases:65.78%
controls:47.75%
cases:14.97%
controls:9.68%
—
—
cases:19.25%
controls:8.55%
cases:63.10%
controls:45.17%
cases:83.69%
controls:70.10%
155
1350
32
520
123
893
64
977
28
181
159
1689
—
36
159
151
1701
106
766
62
930
118
945
23
403
Pharmacy visit
OMOP4822462 [581458]
4.5e-01
5.5e-01
3.4e-01
2.1e+00
3.1e-01
1.1e+00
1.3e+00
cases:96.26%
controls:94.22%
cases:90.37%
controls:84.39%
cases:52.41%
controls:43.96%
cases:16.04%
controls:2.35%
cases:52.41%
controls:44.73%
cases:94.05%
controls:83.73%
cases:98.58%
controls:95.18%
180
1762
7
108
169
1578
18
292
98
822
89
1048
30
44
157
1826
98
832
89
1028
158
1420
10
276
139
1283
2
65
azelaic acid; ointment
D10AX03 [21602314]
—
—
—
1.0e+50
—
2.5e+00
—
—
—
—
—
—
—
cases:2.67%
controls:0.00%
—
—
cases:3.57%
controls:0.29%
—
—
—
—
—
5
0
182
1870
—
6
5
162
1691
—
Gastroenterology
10 [38004455]
9.8e-01
9.5e-01
—
—
—
1.4e+00
8.0e-01
cases:13.37%
controls:5.45%
cases:5.88%
controls:2.35%
—
—
—
—
—
—
cases:7.14%
controls:1.83%
cases:11.35%
controls:5.42%
25
102
162
1768
11
44
176
1826
—
—
—
12
31
156
1665
16
73
125
1275
Laboratory Visit
OMOP4822461 [32036]
3.2e-02
4.4e-02
-1.2e-01
2.3e+00
1.2e-01
1.8e-01
2.5e-02
cases:48.13%
controls:47.33%
cases:43.32%
controls:42.25%
cases:10.16%
controls:11.28%
cases:5.35%
controls:0.53%
cases:13.37%
controls:12.04%
cases:42.86%
controls:38.50%
cases:47.52%
controls:46.88%
90
885
97
985
81
790
106
1080
19
211
168
1659
10
10
177
1860
25
224
162
1636
72
653
96
1043
67
632
74
716
Biopsy of skin and subcutaneous tissue
TQX10 [2001310152]
1.4e+00
—
—
1.0e+50
—
—
2.3e+00
cases:2.67%
controls:0.64%
—
—
—
—
cases:2.67%
controls:0.00%
—
—
—
—
cases:4.26%
controls:0.45%
5
12
182
1858
—
—
5
0
182
1870
—
—
6
6
135
1342
Myalgia
M79.1 [45587062]
6.5e-01
—
—
—
—
2.1e+00
—
cases:4.81%
controls:2.57%
—
—
—
—
—
—
—
—
cases:3.57%
controls:0.47%
—
—
9
48
178
1822
—
—
—
—
6
8
162
1688
—
Hysteroscopic excision of lesion
LCB25 [2001306568]
2.0e+00
—
—
—
—
—
—
cases:3.21%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
181
1862
—
—
—
—
—
—
Dysuria/painful urination
U01 [2002001137]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:0.74%
—
—
—
—
—
—
7
10
134
1338
hydroxocobalamin; parenteral
B03BA03 [21601123]
1.9e+00
1.9e+00
—
—
—
—
1.8e+00
cases:3.74%
controls:0.59%
cases:3.21%
controls:0.48%
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.59%
7
11
180
1859
6
9
181
1861
—
—
—
—
5
8
136
1340
hydroxocobalamin
V03AB33 [21605256]
1.9e+00
1.9e+00
—
—
—
—
1.8e+00
cases:3.74%
controls:0.59%
cases:3.21%
controls:0.48%
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.59%
7
11
180
1859
6
9
181
1861
—
—
—
—
5
8
136
1340
Acute vaginitis
N76.0 [45543891]
9.8e-01
—
—
—
—
—
1.8e+00
cases:2.67%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:0.82%
5
19
182
1851
—
—
—
—
—
7
11
134
1337
General Surgery
2 [38004447]
6.8e-01
1.1e+00
-1.0e+50
—
—
6.4e-01
5.3e-01
cases:25.13%
controls:14.55%
cases:11.23%
controls:4.06%
cases:0.00%
controls:0.43%
—
—
—
—
cases:7.14%
controls:3.89%
cases:20.57%
controls:13.20%
47
272
140
1598
21
76
166
1794
0
8
187
1862
—
—
12
66
156
1630
29
178
112
1170
Human papilloma virus DNA [Presence] in Specimen by NAA with probe detection
49891-5 [3029511]
1.7e+00
—
—
—
—
—
—
cases:5.35%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
10
19
177
1851
—
—
—
—
—
—
Chest pain, unspecified
R07.4 [45558450]
5.4e-01
—
—
—
—
1.7e+00
4.9e-01
cases:5.88%
controls:3.53%
—
—
—
—
—
—
—
—
cases:4.76%
controls:0.94%
cases:6.38%
controls:4.01%
11
66
176
1804
—
—
—
—
8
16
160
1680
9
54
132
1294
meloxicam; oral, parenteral, rectal
M01AC06 [21603965]
8.2e-01
7.1e-01
—
—
-1.0e+50
1.5e+00
5.8e-01
cases:8.02%
controls:3.69%
cases:2.67%
controls:1.34%
—
—
—
—
cases:0.00%
controls:0.27%
cases:6.55%
controls:1.53%
cases:8.51%
controls:4.97%
15
69
172
1801
5
25
182
1845
—
—
0
5
187
1855
11
26
157
1670
12
67
129
1281
Other primary gonarthrosis
M17.1 [45596493]
4.2e-02
-1.0e+50
—
—
—
—
1.3e+00
cases:2.67%
controls:2.57%
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
cases:8.51%
controls:2.37%
5
48
182
1822
0
15
187
1855
—
—
—
—
12
32
129
1316
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
1.2e+00
—
—
—
—
1.3e+00
—
cases:8.02%
controls:2.57%
—
—
—
—
—
—
—
—
cases:3.57%
controls:1.00%
—
—
15
48
172
1822
—
—
—
—
6
17
162
1679
—
montelukast; oral
R03DC03 [21603356]
1.2e-01
3.7e-01
—
—
-1.0e+50
4.8e-01
1.2e+00
cases:4.28%
controls:3.80%
cases:3.74%
controls:2.62%
—
—
—
—
cases:0.00%
controls:0.48%
cases:3.57%
controls:2.24%
cases:10.64%
controls:3.49%
8
71
179
1799
7
49
180
1821
—
—
0
9
187
1851
6
38
162
1658
15
47
126
1301
Coloscopy
UJF32 [2001305029]
1.2e+00
—
—
—
—
—
4.2e-01
cases:9.63%
controls:3.16%
—
—
—
—
—
—
—
—
—
—
cases:5.67%
controls:3.78%
18
59
169
1811
—
—
—
—
—
8
51
133
1297
roxithromycin; oral
J01FA06 [21602974]
1.1e+00
-1.0e+50
—
—
—
1.4e+00
3.9e-01
cases:9.09%
controls:3.32%
cases:0.00%
controls:0.75%
—
—
—
—
—
—
cases:3.57%
controls:0.88%
cases:4.96%
controls:3.41%
17
62
170
1808
0
14
187
1856
—
—
—
6
15
162
1681
7
46
134
1302
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.1e+00
—
—
—
—
—
4.4e-01
cases:9.63%
controls:3.53%
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:3.26%
18
66
169
1804
—
—
—
—
—
7
44
134
1304
Pain localized to other parts of lower abdomen
R10.3 [45534426]
1.0e+00
—
—
—
—
1.2e+00
3.8e-01
cases:10.70%
controls:4.22%
—
—
—
—
—
—
—
—
cases:3.57%
controls:1.12%
cases:5.67%
controls:3.93%
20
79
167
1791
—
—
—
—
6
19
162
1677
8
53
133
1295
Pain in joint
M25.5 [45586941]
3.5e-01
4.7e-01
—
—
—
1.2e+00
9.8e-01
cases:8.02%
controls:5.78%
cases:3.21%
controls:2.03%
—
—
—
—
—
—
cases:5.36%
controls:1.71%
cases:12.77%
controls:5.19%
15
108
172
1762
6
38
181
1832
—
—
—
9
29
159
1667
18
70
123
1278
budesonide; inhalant
R03BA02 [21603285]
7.6e-01
5.0e-01
—
—
-1.0e+50
6.6e-01
9.7e-01
cases:12.30%
controls:6.15%
cases:5.88%
controls:3.64%
—
—
—
—
cases:0.00%
controls:1.13%
cases:6.55%
controls:3.48%
cases:12.77%
controls:5.27%
23
115
164
1755
11
68
176
1802
—
—
0
21
187
1839
11
59
157
1637
18
71
123
1277
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
2.1e-01
2.8e-01
-1.0e+50
—
—
3.1e-01
9.5e-01
cases:13.37%
controls:11.12%
cases:7.49%
controls:5.78%
cases:0.00%
controls:0.48%
—
—
—
—
cases:5.95%
controls:4.42%
cases:20.57%
controls:9.12%
25
208
162
1662
14
108
173
1762
0
9
187
1861
—
—
10
75
158
1621
29
123
112
1225
Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep
18500-9 [3018006]
9.1e-01
—
—
—
—
—
2.7e-01
cases:13.90%
controls:6.10%
—
—
—
—
—
—
—
—
—
—
cases:5.67%
controls:4.38%
26
114
161
1756
—
—
—
—
—
8
59
133
1289
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
3.5e-01
0.0e+00
—
—
—
6.3e-01
9.0e-01
cases:12.83%
controls:9.41%
cases:4.81%
controls:4.81%
—
—
—
—
—
—
cases:7.14%
controls:3.95%
cases:17.73%
controls:8.09%
24
176
163
1694
9
90
178
1780
—
—
—
12
67
156
1629
25
109
116
1239
salbutamol; inhalant
R03AC02 [21603256]
4.5e-01
3.5e-01
—
—
—
6.9e-01
8.6e-01
cases:22.46%
controls:15.56%
cases:11.23%
controls:8.18%
—
—
—
—
—
—
cases:14.29%
controls:7.72%
cases:29.08%
controls:14.84%
42
291
145
1579
21
153
166
1717
—
—
—
24
131
144
1565
41
200
100
1148
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
8.2e-01
1.3e+00
-1.0e+50
—
—
9.1e-01
8.5e-01
cases:13.90%
controls:6.63%
cases:5.35%
controls:1.55%
cases:0.00%
controls:0.32%
—
—
—
—
cases:3.57%
controls:1.47%
cases:10.64%
controls:4.82%
26
124
161
1746
10
29
177
1841
0
6
187
1864
—
—
6
25
162
1671
15
65
126
1283
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
7.7e-01
3.4e-01
-1.0e+50
—
—
9.5e-01
4.2e-01
cases:14.44%
controls:7.22%
cases:3.21%
controls:2.30%
cases:0.00%
controls:0.53%
—
—
—
—
cases:4.17%
controls:1.65%
cases:9.93%
controls:6.75%
27
135
160
1735
6
43
181
1827
0
10
187
1860
—
—
7
28
161
1668
14
91
127
1257
prednisolone; oral, parenteral
H02AB06 [21602734]
7.7e-01
5.0e-01
—
—
—
8.2e-01
7.3e-01
cases:19.79%
controls:10.27%
cases:6.95%
controls:4.33%
—
—
—
—
—
—
cases:8.93%
controls:4.13%
cases:18.44%
controls:9.87%
37
192
150
1678
13
81
174
1789
—
—
—
15
70
153
1626
26
133
115
1215
Internal Medicine
11 [38004456]
5.6e-01
5.1e-01
—
—
—
4.6e-01
7.6e-01
cases:25.67%
controls:16.52%
cases:10.16%
controls:6.36%
—
—
—
—
—
—
cases:8.93%
controls:5.84%
cases:28.37%
controls:15.65%
48
309
139
1561
19
119
168
1751
—
—
—
15
99
153
1597
40
211
101
1137
prednisolone
A07EA01 [21600653]
7.6e-01
4.9e-01
—
—
—
8.1e-01
7.3e-01
cases:19.79%
controls:10.37%
cases:6.95%
controls:4.39%
—
—
—
—
—
—
cases:8.93%
controls:4.19%
cases:18.44%
controls:9.87%
37
194
150
1676
13
82
174
1788
—
—
—
15
71
153
1625
26
133
115
1215
Upper gastrointestinal surgery
106 [44777669]
7.3e-01
3.9e-01
-1.0e+50
—
—
7.8e-01
6.3e-01
cases:16.04%
controls:8.40%
cases:4.28%
controls:2.94%
cases:0.00%
controls:0.27%
—
—
—
—
cases:4.76%
controls:2.24%
cases:12.06%
controls:6.82%
30
157
157
1713
8
55
179
1815
0
5
187
1865
—
—
8
38
160
1658
17
92
124
1256
Emergency Room Visit
ER [9203]
2.6e-01
3.4e-01
—
—
-1.0e+50
5.6e-01
6.3e-01
cases:32.62%
controls:27.22%
cases:11.76%
controls:8.66%
—
—
—
—
cases:0.00%
controls:0.97%
cases:11.31%
controls:6.78%
cases:38.30%
controls:24.85%
61
509
126
1361
22
162
165
1708
—
—
0
18
187
1842
19
115
149
1581
54
335
87
1013
Tinea pedis
B35.3 [45581158]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
141
1342
Fitting of hearing aid
DAX08 [2001301529]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
0
7
187
1863
0
5
187
1865
—
—
—
—
—
hepatitis A, inactivated, whole virus
J07BC02 [21601339]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
187
1861
—
—
—
—
—
—
Lipid disorder
T93 [2002001134]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.64%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
0
12
187
1858
0
6
187
1864
—
—
—
—
—
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
6.5e-01
—
—
—
—
—
—
cases:4.81%
controls:2.57%
—
—
—
—
—
—
—
—
—
—
—
—
9
48
178
1822
—
—
—
—
—
—
Elevated blood pressure
K85 [2002000612]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
0
15
187
1855
0
5
187
1865
—
—
—
—
Triglyceride [Moles/volume] in Serum or Plasma
14927-8 [3025839]
-9.0e-02
-2.7e-01
-1.0e+50
—
-1.0e+50
3.9e-01
1.6e-01
cases:4.81%
controls:5.24%
cases:3.21%
controls:4.17%
cases:0.00%
controls:0.53%
—
—
cases:0.00%
controls:0.59%
cases:5.95%
controls:4.13%
cases:10.64%
controls:9.20%
9
98
178
1772
6
78
181
1792
0
10
187
1860
—
0
11
187
1849
10
70
158
1626
15
124
126
1224
Recurrent depressive disorder, unspecified
F33.9 [45581458]
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
0
7
187
1863
0
5
187
1865
—
—
—
—
Primary total prosthetic replacement of hip joint using hybrid technique
NFB40 [2001307922]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
141
1343
Hypothyroidism/myxoedema
T86 [2002001128]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
0
5
187
1865
—
—
—
0
5
168
1691
—
Hallux valgus (acquired)
M20.1 [45606152]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
7
168
1689
—
Audiometric test
21727005 [4071702]
—
—
—
—
—
-1.0e+50
9.8e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
cases:4.26%
controls:1.63%
—
—
—
—
—
0
9
168
1687
6
22
135
1326
Chronic ulcer skin
S97 [2002001061]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
141
1343
Bacteria identified in Cerebral spinal fluid by Culture
606-4 [3016914]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Retained molar with obstruction in the upper jaw
K01.16 [2000502661]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
—
Lambda light chains.free [Mass/volume] in Serum or Plasma
33944-0 [3047169]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
8
141
1340
Consultation of another employee
SPAT1260 [2001700361]
-7.9e-02
—
—
—
—
-1.0e+50
—
cases:2.67%
controls:2.89%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
5
54
182
1816
—
—
—
—
0
13
168
1683
—
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
3.4e-01
7.1e-01
—
—
—
—
3.7e-01
cases:5.35%
controls:3.85%
cases:2.67%
controls:1.34%
—
—
—
—
—
—
—
—
cases:4.96%
controls:3.49%
10
72
177
1798
5
25
182
1845
—
—
—
—
7
47
134
1301
Asthma, unspecified
J45.9 [45562456]
3.4e-01
—
—
—
—
1.2e+00
8.1e-01
cases:4.81%
controls:3.48%
—
—
—
—
—
—
—
—
cases:4.76%
controls:1.53%
cases:7.80%
controls:3.64%
9
65
178
1805
—
—
—
—
8
26
160
1670
11
49
130
1299
Melanocytic naevi, unspecified
D22.9 [45571603]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
—
—
—
—
—
—
8.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:1.85%
—
—
—
—
—
—
6
25
135
1323
indometacin; oral, parenteral, rectal
M01AB01 [21603941]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
187
1859
—
—
—
—
—
—
Glutamate decarboxylase 65 Ab [Units/volume] in Serum
13926-1 [3020148]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
187
1861
—
—
—
—
—
—
Base excess in Arterial blood by calculation
1925-7 [3003396]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
6
168
1690
—
erdosteine; oral
R05CB15 [21603394]
4.9e-01
—
—
—
—
1.1e+00
6.2e-01
cases:4.28%
controls:2.67%
—
—
—
—
—
—
—
—
cases:3.57%
controls:1.24%
cases:4.96%
controls:2.74%
8
50
179
1820
—
—
—
—
6
21
162
1675
7
37
134
1311
Zoster without complication
B02.9 [45581143]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
hydrochlorothiazide and potassium-sparing agents
C03EA01 [21601543]
1.3e-01
—
—
—
—
—
—
cases:3.21%
controls:2.83%
—
—
—
—
—
—
—
—
—
—
—
—
6
53
181
1817
—
—
—
—
—
—
Radical radiotherapy
WF002 [2001310701]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
187
1862
—
—
—
—
—
—
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 [3034780]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
0
8
187
1862
—
—
—
0
8
168
1688
—
Fear endocrine/metabol disease other
T27 [2002001075]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Pregnancy high risk
W84 [2002001275]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
0
15
187
1855
—
—
—
—
—
0
6
141
1342
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: occasional
SMOKING-1-1-2 [2002330117]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
—
Otitis media, unspecified
H66.9 [45547965]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
6
168
1690
—
Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture
13317-3 [3019902]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
0
11
187
1859
—
—
—
—
0
14
141
1334
rivaroxaban; oral
B01AF01 [43534761]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
0
8
187
1862
—
—
—
—
Treatment of reopened or infected surgical wound
SPAT1144 [2001700245]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
187
1859
—
—
—
—
—
—
FEV1/FVC --post bronchodilation
69970-2 [42868459]
—
-1.0e+50
—
—
—
—
1.7e+00
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.67%
—
0
14
187
1856
—
—
—
—
5
9
136
1339
Recurrent depression, moderate episode of somatic syndrome
F33.11 [2000501985]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
—
lidocaine
C05AD01 [21601618]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
—
Lumbar spine MRI examination with high intensity magnet
NA3BG [2001307034]
—
-1.0e+50
—
—
—
—
1.6e+00
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.74%
—
0
8
187
1862
—
—
—
—
5
10
136
1338
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
7
168
1689
—
tizanidine; oral
M03BX02 [21604116]
2.9e-01
5.3e-01
—
—
—
5.7e-01
-1.1e-01
cases:19.25%
controls:15.19%
cases:6.95%
controls:4.22%
—
—
—
—
—
—
cases:7.74%
controls:4.54%
cases:14.18%
controls:15.58%
36
284
151
1586
13
79
174
1791
—
—
—
13
77
155
1619
20
210
121
1138
tafluprost
S01EE05 [21603714]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
187
1863
—
—
—
—
—
—
flecainide; oral, parenteral
C01BC04 [21600266]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.48%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
0
10
187
1860
0
9
187
1861
—
—
—
0
7
168
1689
—
Opiates [Presence] in Urine
3879-4 [3027008]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
0
7
187
1863
—
—
—
0
7
168
1689
—
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
2.3e-01
1.3e-01
-1.0e+50
—
-1.0e+50
6.4e-01
1.4e-01
cases:8.56%
controls:6.90%
cases:3.74%
controls:3.32%
cases:0.00%
controls:0.64%
—
—
cases:0.00%
controls:0.38%
cases:4.17%
controls:2.24%
cases:8.51%
controls:7.49%
16
129
171
1741
7
62
180
1808
0
12
187
1858
—
0
7
187
1853
7
38
161
1658
12
101
129
1247
glycerol
A06AX01 [21600597]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Exercise ECG
SPAT1098 [2001700199]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Systemic arterial pressure
364090009 [4238447]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
—
desonide
D07AB08 [21602112]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.11%
—
0
8
187
1862
—
—
—
—
0
15
141
1333
Maternal care for excessive fetal growth
O36.6 [45543983]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
8
187
1862
—
—
—
—
—
0
7
141
1341
ciclesonide; nasal
R01AD13 [43534836]
7.8e-01
—
-1.0e+50
—
—
—
—
cases:3.21%
controls:1.50%
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
6
28
181
1842
—
0
5
187
1865
—
—
—
—
ethinylestradiol; oral
G03CA01 [21602516]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
12
187
1858
—
—
—
—
—
0
5
141
1343
Open wound of scalp
S01.0 [45592468]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
187
1857
—
—
—
—
—
—
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
-1.3e-01
-1.6e-01
-1.0e+50
—
—
3.8e-02
2.3e-01
cases:25.13%
controls:27.59%
cases:15.51%
controls:17.75%
cases:0.00%
controls:1.28%
—
—
—
—
cases:16.07%
controls:15.57%
cases:32.62%
controls:27.74%
47
516
140
1354
29
332
158
1538
0
24
187
1846
—
—
27
264
141
1432
46
374
95
974
haloperidol; oral, parenteral
N05AD01 [21604516]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Knee symptom/complaint
L15 [2002000639]
2.9e-01
—
-1.0e+50
—
—
—
1.2e+00
cases:5.35%
controls:4.06%
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
cases:7.80%
controls:2.60%
10
76
177
1794
—
0
5
187
1865
—
—
—
11
35
130
1313
Celiac disease serology panel - Serum
94494-2 [36660697]
-9.8e-02
—
—
—
—
—
—
cases:2.67%
controls:2.94%
—
—
—
—
—
—
—
—
—
—
—
—
5
55
182
1815
—
—
—
—
—
—
temazepam; oral
N05CD07 [21604642]
—
—
—
—
—
9.4e-01
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:2.98%
controls:1.18%
cases:4.96%
controls:1.85%
—
—
—
—
—
5
20
163
1676
7
25
134
1323
Pharmacological induction or advancement of labor
MAC40 [2001306872]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
—
colecalciferol; oral
A11CC05 [21600820]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
7
141
1341
pimecrolimus
D11AH02 [21602339]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
0
5
187
1865
—
—
—
—
0
6
141
1342
Trigger finger
M65.3 [45538828]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
11
141
1337
Telephone prescription or other care instructions
WZB00 [2001310884]
6.3e-01
-1.0e+50
—
—
—
—
9.0e-01
cases:8.02%
controls:4.44%
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
cases:7.80%
controls:3.34%
15
83
172
1787
0
15
187
1855
—
—
—
—
11
45
130
1303
Neurosurgery
14 [38004459]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
cases:0.00%
controls:1.00%
—
—
—
—
0
5
187
1865
—
—
0
17
168
1679
—
Physiotherapy
R4110 [2001310233]
4.2e-01
—
-1.0e+50
—
-1.0e+50
—
1.9e-01
cases:5.35%
controls:3.58%
—
—
cases:0.00%
controls:0.37%
—
—
cases:0.00%
controls:0.27%
—
—
cases:4.26%
controls:3.56%
10
67
177
1803
—
0
7
187
1863
—
0
5
187
1855
—
6
48
135
1300
Hearing complaint
H02 [2002000476]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.67%
controls:2.15%
—
—
—
—
—
—
8
29
133
1319
Other diagnostic examination of periferal vessel
XPX99 [2001309755]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
187
1861
—
—
—
—
—
—
Therapeutic Radiology Physician
2085R0203X [38004006]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
0
8
187
1862
0
6
187
1864
—
—
—
—
—
gabapentin; oral
N02BF01 [955005]
3.9e-01
5.0e-01
—
—
—
5.7e-01
3.5e-01
cases:4.81%
controls:3.32%
cases:3.21%
controls:1.98%
—
—
—
—
—
—
cases:2.98%
controls:1.71%
cases:4.26%
controls:3.04%
9
62
178
1808
6
37
181
1833
—
—
—
5
29
163
1667
6
41
135
1307
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
5.2e-01
—
—
—
—
-1.0e+50
7.5e-01
cases:3.21%
controls:1.93%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
cases:3.55%
controls:1.71%
6
36
181
1834
—
—
—
—
0
9
168
1687
5
23
136
1325
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
3.5e-01
4.1e-01
—
—
—
9.2e-01
4.2e-01
cases:9.63%
controls:7.01%
cases:3.74%
controls:2.51%
—
—
—
—
—
—
cases:4.76%
controls:1.95%
cases:8.51%
controls:5.79%
18
131
169
1739
7
47
180
1823
—
—
—
8
33
160
1663
12
78
129
1270
Loss of teeth due to accident, extraction or local periodontal disease
K08.1 [45591573]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.27%
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
0
11
187
1859
0
5
187
1865
—
—
0
11
168
1685
—
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD)/1.73 sq M
77147-7 [46236952]
1.4e+00
-1.0e+50
—
—
—
—
—
cases:4.81%
controls:1.18%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
9
22
178
1848
0
6
187
1864
—
—
—
—
—
Physical Medicine And Rehabilitation
25 [38004468]
1.7e-01
4.9e-01
-1.0e+50
—
—
9.2e-01
8.9e-01
cases:9.09%
controls:7.81%
cases:4.28%
controls:2.67%
cases:0.00%
controls:0.53%
—
—
—
—
cases:4.17%
controls:1.71%
cases:13.48%
controls:6.01%
17
146
170
1724
8
50
179
1820
0
10
187
1860
—
—
7
29
161
1667
19
81
122
1267
Benign and innocent cardiac murmurs
R01.0 [45563286]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Cough
R05 [45606792]
5.9e-01
—
—
—
—
1.5e+00
8.5e-01
cases:4.81%
controls:2.73%
—
—
—
—
—
—
—
—
cases:2.98%
controls:0.65%
cases:6.38%
controls:2.82%
9
51
178
1819
—
—
—
—
5
11
163
1685
9
38
132
1310
Lupus anticoagulant assay
63300003 [4268621]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
187
1863
—
—
—
—
—
—
Sprain and strain involving (anterior)(posterior) cruciate ligament of knee
S83.5 [45608523]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
0
8
141
1340
Enthesopathy, unspecified
M77.9 [45591933]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
187
1861
—
—
—
—
—
—
Contusion of knee
S80.0 [45569633]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.96%
controls:0.89%
—
—
—
—
—
—
7
12
134
1336
Excessive and frequent menstruation with regular cycle
N92.0 [45577544]
1.3e+00
—
—
—
—
—
—
cases:3.74%
controls:1.07%
—
—
—
—
—
—
—
—
—
—
—
—
7
20
180
1850
—
—
—
—
—
—
Human papilloma virus E6+E7 mRNA [Presence] in Cervix by NAA with probe detection
69002-4 [40771527]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Intravenous administration of medicine
SPAT1255 [2001700356]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
—
—
—
—
—
—
0
17
187
1853
—
—
—
—
—
—
tibolone; oral
G03CX01 [21602536]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.59%
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
0
11
187
1859
0
10
187
1860
—
—
—
0
10
168
1686
—
Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma
12841-3 [3001784]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
Fitting and adjustment of hearing aid
Z46.1 [45595518]
—
-1.0e+50
—
—
—
—
1.9e+00
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.52%
—
0
5
187
1865
—
—
—
—
5
7
136
1341
Issue of repeat prescription
Z76.0 [45542456]
-1.7e-01
2.7e-01
—
—
—
4.4e-01
6.3e-01
cases:2.67%
controls:3.16%
cases:3.21%
controls:2.46%
—
—
—
—
—
—
cases:2.98%
controls:1.95%
cases:9.22%
controls:5.12%
5
59
182
1811
6
46
181
1824
—
—
—
5
33
163
1663
13
69
128
1279
Reaction to severe stress, and adjustment disorders
F43 [45557206]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Structured assessment of psychoactive substance / tobacco use
SPAT1273 [2001700374]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
187
1862
—
—
—
—
—
—
Premature rupture of membranes, onset of labour after 24 hours
O42.1 [45534269]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Sexual health counselling
SPAT1308 [2001700409]
2.1e-01
-1.0e+50
—
—
—
—
—
cases:3.21%
controls:2.62%
cases:0.00%
controls:0.80%
—
—
—
—
—
—
—
—
—
—
6
49
181
1821
0
15
187
1855
—
—
—
—
—
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
5.9e-02
3.5e-01
-1.0e+50
—
—
5.6e-01
3.9e-01
cases:20.86%
controls:19.89%
cases:10.70%
controls:7.81%
cases:0.00%
controls:0.64%
—
—
—
—
cases:10.71%
controls:6.43%
cases:20.57%
controls:14.91%
39
372
148
1498
20
146
167
1724
0
12
187
1858
—
—
18
109
150
1587
29
201
112
1147
Orthostatic hypotension
I95.1 [45605872]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
—
Stomatognathic treatment, simple
SHA01 [2001310405]
2.3e-01
—
—
—
—
-1.0e+50
—
cases:2.67%
controls:2.14%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.77%
—
—
5
40
182
1830
—
—
—
—
0
13
168
1683
—
Coronary angiography
AN1 [2000200163]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
0
14
187
1856
0
7
187
1863
—
—
—
—
—
glyceryl trinitrate
C05AE01 [21601626]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Atrial fibrillation and flutter
I48 [45596206]
—
-1.0e+50
-1.0e+50
—
—
—
3.2e-01
—
—
cases:0.00%
controls:1.71%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:3.55%
controls:2.60%
—
0
32
187
1838
0
7
187
1863
—
—
—
5
35
136
1313
Fractional oxyhemoglobin in Venous blood
2716-9 [3019230]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
141
1342
Disorders of lipoprotein metabolism and other lipidaemias
E78 [45557140]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
0
7
187
1863
—
—
—
—
—
0
6
141
1342
diltiazem; oral
C08DB01 [21601771]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.80%
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
0
15
187
1855
0
10
187
1860
—
—
—
—
—
Cathetrisation of artery
TPH07 [2001309747]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
5
168
1691
—
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
0
11
187
1859
—
—
—
—
—
clonazepam; oral, parenteral
N03AE01 [21604415]
1.3e+00
—
—
—
—
—
—
cases:2.67%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
—
5
14
182
1856
—
—
—
—
—
—
Upper respiratory infection acute
R74 [2002000942]
1.5e-01
—
—
—
-1.0e+50
—
1.7e-01
cases:9.09%
controls:7.91%
—
—
—
—
—
—
cases:0.00%
controls:0.38%
—
—
cases:9.22%
controls:7.86%
17
148
170
1722
—
—
—
0
7
187
1853
—
13
106
128
1242
phenylephrine, combinations
S01GA55 [21605082]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
Sprain and strain of ankle
S93.4 [45550848]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
5
168
1691
—
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
4.3e-01
—
—
—
—
1.2e+00
3.0e-01
cases:5.88%
controls:3.90%
—
—
—
—
—
—
—
—
cases:2.98%
controls:0.94%
cases:4.96%
controls:3.71%
11
73
176
1797
—
—
—
—
5
16
163
1680
7
50
134
1298
Eye infection/inflammation other
F73 [2002000456]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
Other disorders of vitreous body
H43.8 [45533329]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
0
10
187
1860
—
—
—
0
5
168
1691
—
chlorhexidine
S03AA04 [21605193]
9.7e-01
-1.0e+50
—
—
—
—
—
cases:4.81%
controls:1.87%
cases:0.00%
controls:0.70%
—
—
—
—
—
—
—
—
—
—
9
35
178
1835
0
13
187
1857
—
—
—
—
—
Examination of eyes and vision
Z01.0 [45566391]
5.8e-01
—
—
—
—
—
4.8e-01
cases:3.74%
controls:2.14%
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:2.67%
7
40
180
1830
—
—
—
—
—
6
36
135
1312
betahistine; oral
N07CA01 [21604833]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
0
5
187
1865
—
—
—
0
6
168
1690
—
Protein C actual/normal in Platelet poor plasma by Coagulation assay
27819-2 [3020287]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
187
1863
—
—
—
—
—
—
Endovenous obliteration of other vein
PHM99 [2001309542]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
187
1863
—
—
—
—
—
—
Hand/finger symptom/complaint
L12 [2002000636]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
—
0
8
168
1688
—
Senile incipient cataract
H25.0 [45576699]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
5
168
1691
—
valsartan and diuretics
C09DA03 [21601836]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:0.00%
controls:0.53%
cases:0.00%
controls:0.74%
—
0
10
187
1860
—
—
—
0
9
168
1687
0
10
141
1338
Balloon angioplasty and drug eluding stent
AN4 [2000200166]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
fluocinolone acetonide and antiinfectives
S02CA05 [21605177]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
5
168
1691
—
Preventive oral health care, extensive
SCA03 [2001310304]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
187
1860
—
—
—
—
—
—
Cytology report of Tissue fine needle aspirate Cyto stain
33718-8 [3043109]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
azithromycin; oral, parenteral
J01FA10 [21602978]
2.2e-01
-9.8e-02
—
—
—
9.5e-01
4.7e-01
cases:11.23%
controls:9.25%
cases:2.67%
controls:2.94%
—
—
—
—
—
—
cases:4.76%
controls:1.89%
cases:12.77%
controls:8.38%
21
173
166
1697
5
55
182
1815
—
—
—
8
32
160
1664
18
113
123
1235
Remowal of suture of skin
TQW40 [2001310146]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
—
—
0
12
187
1858
—
—
—
—
—
—
insulin aspart; parenteral
A10AD05 [21600733]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
Fall on same level involving ice and snow
W00 [45756242]
1.4e+00
—
—
—
—
—
1.3e+00
cases:2.67%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:1.04%
5
12
182
1858
—
—
—
—
—
5
14
136
1334
Osmolality of Urine
2695-5 [3026782]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.38%
controls:2.00%
—
—
—
—
—
—
9
27
132
1321
metformin; oral
A10BA02 [21600747]
-5.1e-01
—
—
—
-1.0e+50
—
—
cases:4.28%
controls:6.90%
—
—
—
—
—
—
cases:0.00%
controls:1.77%
—
—
—
—
8
129
179
1741
—
—
—
0
33
187
1827
—
—
Cholesterol in LDL [Moles/volume] in Serum or Plasma
22748-8 [3001308]
1.3e-01
-1.4e-02
—
—
—
3.1e-01
1.8e-01
cases:36.90%
controls:33.96%
cases:19.25%
controls:19.47%
—
—
—
—
—
—
cases:23.21%
controls:18.10%
cases:36.17%
controls:32.05%
69
635
118
1235
36
364
151
1506
—
—
—
39
307
129
1389
51
432
90
916
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
4.5e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:5.35%
controls:3.48%
cases:0.00%
controls:0.80%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
10
65
177
1805
0
15
187
1855
—
—
—
0
10
168
1686
—
Limited function/disability NOS
A28 [2002000162]
—
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
cases:0.00%
controls:0.83%
—
—
—
—
0
8
187
1862
—
—
0
14
168
1682
—
codeine and paracetamol
N02AJ06 [1123647]
2.1e-01
1.3e-01
9.8e-01
—
—
9.8e-02
2.8e-01
cases:15.51%
controls:12.99%
cases:6.95%
controls:6.15%
cases:2.67%
controls:1.02%
—
—
—
—
cases:5.95%
controls:5.42%
cases:17.02%
controls:13.43%
29
243
158
1627
13
115
174
1755
5
19
182
1851
—
—
10
92
158
1604
24
181
117
1167
Acute bronchitis, unspecified
J20.9 [45562445]
3.9e-01
—
—
—
—
—
4.1e-01
cases:2.67%
controls:1.82%
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.37%
5
34
182
1836
—
—
—
—
—
5
32
136
1316
Acute inflammatory disease of uterus
N71.0 [45596880]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.48%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
0
9
187
1861
0
5
187
1865
—
—
—
—
—
polymyxin B
S01AA18 [21603569]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
naproxen and esomeprazole; oral
M01AE52 [40254096]
4.2e-02
—
—
—
—
—
—
cases:2.67%
controls:2.57%
—
—
—
—
—
—
—
—
—
—
—
—
5
48
182
1822
—
—
—
—
—
—
ganirelix; parenteral
H01CC01 [21602720]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
187
1862
—
—
—
—
—
—
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
117 [2001600117]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Lumbar spine X-ray examination without contrast
NA3AA [2001307026]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
0
8
187
1862
—
—
—
—
—
Fracture of tooth, open
S02.51 [45755762]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
0
19
187
1851
—
—
—
—
—
—
Public health laboratory ask at order entry panel
81959-9 [21494755]
2.5e-01
-1.0e+50
—
—
—
-1.0e+50
—
cases:3.74%
controls:2.94%
cases:0.00%
controls:0.53%
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
7
55
180
1815
0
10
187
1860
—
—
—
0
12
168
1684
—
quetiapine; oral
N05AH04 [21604544]
1.9e-01
—
—
—
-1.0e+50
—
—
cases:3.74%
controls:3.10%
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
7
58
180
1812
—
—
—
0
14
187
1846
—
—
Normoblasts [#/volume] in Blood
715-3 [3021589]
2.0e-02
-2.1e-01
—
—
—
1.6e-01
7.6e-02
cases:12.30%
controls:12.09%
cases:6.95%
controls:8.45%
—
—
—
—
—
—
cases:8.33%
controls:7.19%
cases:10.64%
controls:9.94%
23
226
164
1644
13
158
174
1712
—
—
—
14
122
154
1574
15
134
126
1214
Depressive episode, unspecified
F32.9 [45571760]
—
—
—
—
—
—
8.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:1.48%
—
—
—
—
—
—
5
20
136
1328
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
4.1e-01
-5.0e-02
—
—
—
1.4e-01
8.0e-01
cases:10.70%
controls:7.38%
cases:3.21%
controls:3.37%
—
—
—
—
—
—
cases:2.98%
controls:2.59%
cases:13.48%
controls:6.53%
20
138
167
1732
6
63
181
1807
—
—
—
5
44
163
1652
19
88
122
1260
Fracture of upper end of radius
S52.1 [45535152]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
141
1343
Atherosclerotic heart disease
I25.1 [45596196]
—
—
—
—
-1.0e+50
—
3.8e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
cases:3.55%
controls:2.45%
—
—
—
—
0
5
187
1855
—
5
33
136
1315
clidinium and psycholeptics
A03CA02 [21600204]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
0
7
187
1863
—
—
—
0
7
168
1689
—
Obstetric epidural analgesia
WX307 [2001310797]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
Fetal Nuchal fold Thickness US
12146-7 [3005033]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
Polyp of corpus uteri
N84.0 [45596887]
1.5e+00
—
—
—
—
-1.0e+50
—
cases:3.21%
controls:0.75%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
6
14
181
1856
—
—
—
—
0
5
168
1691
—
racecadotril
A07XA04 [21600677]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
—
SMOKING - SMOKE2: no - SMOKE3: former - SMOKE5: former
SMOKING-2-2-4 [2002330109]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.55%
—
—
—
—
—
—
—
—
—
—
—
—
0
29
187
1841
—
—
—
—
—
—
Unilateral lobectomy of thyroid gland
BAA40 [2001300751]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
187
1863
—
—
—
—
—
—
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
9.9e-02
—
—
—
—
1.1e+00
3.1e-01
cases:5.35%
controls:4.87%
—
—
—
—
—
—
—
—
cases:2.98%
controls:1.00%
cases:5.67%
controls:4.23%
10
91
177
1779
—
—
—
—
5
17
163
1679
8
57
133
1291
Cardiorespiratory global assessment
SPAT1081 [2001700182]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
187
1860
—
—
—
—
—
—
Aortic (valve) stenosis
I35.0 [45576869]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
0
8
187
1862
—
—
—
—
—
Repair work or maintenance done on the aid
R5130 [2001310248]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
0
7
141
1341
Differential panel, method unspecified - Blood
69738-3 [42870588]
2.5e-01
2.0e-01
-1.0e+50
—
—
3.3e-01
-2.0e-01
cases:10.70%
controls:8.50%
cases:4.81%
controls:3.96%
cases:0.00%
controls:0.48%
—
—
—
—
cases:4.76%
controls:3.48%
cases:4.96%
controls:6.01%
20
159
167
1711
9
74
178
1796
0
9
187
1861
—
—
8
59
160
1637
7
81
134
1267
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
-1.7e-01
7.1e-02
—
—
—
—
5.4e-01
cases:7.49%
controls:8.77%
cases:3.21%
controls:2.99%
—
—
—
—
—
—
—
—
cases:9.22%
controls:5.56%
14
164
173
1706
6
56
181
1814
—
—
—
—
13
75
128
1273
Other internal derangements of knee
M23.8 [45548371]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
5
187
1865
—
—
—
—
—
0
5
141
1343
Measurement of mechanical axis of lower leg with X-ray
NJ2MA [2001308419]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
141
1343
Pure hypercholesterolaemia
E78.0 [45542771]
7.4e-01
—
—
—
—
—
—
cases:4.81%
controls:2.35%
—
—
—
—
—
—
—
—
—
—
—
—
9
44
178
1826
—
—
—
—
—
—
Extended examination of mouth
SAA03 [2001310276]
5.3e-01
—
—
—
—
—
6.0e-01
cases:9.09%
controls:5.56%
—
—
—
—
—
—
—
—
—
—
cases:10.64%
controls:6.16%
17
104
170
1766
—
—
—
—
—
15
83
126
1265
loratadine; oral
R06AX13 [21603514]
8.2e-01
—
—
—
—
—
—
cases:4.28%
controls:1.93%
—
—
—
—
—
—
—
—
—
—
—
—
8
36
179
1834
—
—
—
—
—
—
Adjuvant radiotherapy
WF003 [2001310702]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
141
1343
Myoglobin [Mass/volume] in Serum or Plasma
2639-3 [3005895]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
187
1863
—
—
—
—
—
—
Internal fixation of fracture of ankle using wire, rod, cerclage or pin
NHJ10 [2001308333]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
141
1343
Urine symptom/complaint other
U07 [2002001142]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.96%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
0
18
187
1852
0
6
187
1864
—
—
—
—
—
Extensive CT examination of arteria pulmonalis
FB1BD [2001302407]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
187
1861
—
—
—
—
—
—
Elbow symptom/complaint
L10 [2002000634]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
0
9
187
1861
—
—
—
—
0
11
141
1337
clopidogrel; oral
B01AC04 [21600989]
—
—
—
—
-1.0e+50
—
9.4e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
cases:4.26%
controls:1.71%
—
—
—
—
0
6
187
1854
—
6
23
135
1325
Routine postpartum follow-up
Z39.2 [45547306]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
0
15
187
1855
—
—
—
0
10
168
1686
—
Orthostatic test
SPAT1101 [2001700202]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Thyrotropin receptor Ab [Units/volume] in Serum
5385-0 [3017044]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
0
5
187
1865
—
—
—
—
0
8
141
1340
megestrol; oral
G03DB02 [21602545]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
187
1859
—
—
—
—
—
—
lynestrenol
G03AC02 [21602498]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Cutaneous abscess, furuncle and carbuncle of trunk
L02.2 [45586751]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
187
1859
—
—
—
—
—
—
Other general examinations
Z00.8 [45581001]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
venlafaxine; oral
N06AX16 [21604745]
8.3e-01
—
-1.0e+50
—
—
—
5.5e-01
cases:5.35%
controls:2.41%
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:3.55%
controls:2.08%
10
45
177
1825
—
0
7
187
1863
—
—
—
5
28
136
1320
Other sleep disorders
G47.8 [45581501]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
141
1343
Other specified counselling
Z71.8 [45581061]
-8.0e-02
7.8e-01
-1.0e+50
—
—
—
7.3e-01
cases:6.95%
controls:7.49%
cases:6.42%
controls:3.05%
cases:0.00%
controls:0.64%
—
—
—
—
—
—
cases:10.64%
controls:5.42%
13
140
174
1730
12
57
175
1813
0
12
187
1858
—
—
—
15
73
126
1275
Hypertensive heart disease without (congestive) heart failure
I11.9 [45576863]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
8
187
1862
—
—
—
—
—
0
7
141
1341
Foot and toes X-ray examination
NH3AA [2001308267]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:1.26%
—
—
—
—
—
—
5
17
136
1331
Supervision of other normal pregnancy
Z34.8 [45537628]
—
—
—
—
—
—
1.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:1.56%
—
—
—
—
—
—
6
21
135
1327
Hyperplasia of prostate
N40 [45563015]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
187
1862
—
—
—
—
—
—
Apolipoprotein B/Apolipoprotein A-I [Percentile]
9340-1 [3011831]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
187
1862
—
—
—
—
—
—
Bacteria identified in Urine by Culture
630-4 [3026008]
1.1e-01
2.9e-01
-1.0e+50
—
-1.0e+50
—
3.0e-01
cases:7.49%
controls:6.74%
cases:3.74%
controls:2.83%
cases:0.00%
controls:0.37%
—
—
cases:0.00%
controls:0.32%
—
—
cases:9.22%
controls:6.97%
14
126
173
1744
7
53
180
1817
0
7
187
1863
—
0
6
187
1854
—
13
94
128
1254
ethinylestradiol; oral
L02AA03 [21603817]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
12
187
1858
—
—
—
—
—
0
5
141
1343
Rupture of aminiotic membrane for induction of labor
MAC01 [2001306869]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
187
1863
—
—
—
—
—
—
Other investigative procedure of eye
XCW99 [2001301491]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
Presence of orthopaedic joint implants
Z96.6 [45600385]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
0
8
187
1862
—
—
—
—
—
Acute upper respiratory infection, unspecified
J06.9 [45562437]
1.6e-01
-8.1e-02
—
—
—
1.7e-01
5.3e-01
cases:13.37%
controls:11.60%
cases:5.35%
controls:5.78%
—
—
—
—
—
—
cases:7.14%
controls:6.07%
cases:19.86%
controls:12.69%
25
217
162
1653
10
108
177
1762
—
—
—
12
103
156
1593
28
171
113
1177
sotalol; oral, parenteral
C07AA07 [21601672]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
cases:0.00%
controls:0.35%
cases:0.00%
controls:0.45%
0
7
187
1863
0
6
187
1864
—
—
—
0
6
168
1690
0
6
141
1342
opium derivatives and expectorants
R05FA02 [21603439]
4.9e-01
—
—
—
—
—
—
cases:2.67%
controls:1.66%
—
—
—
—
—
—
—
—
—
—
—
—
5
31
182
1839
—
—
—
—
—
—
Gingivitis (chronic) NOS
K05.10 [2000502717]
-4.0e-02
—
—
—
—
—
2.1e-01
cases:2.67%
controls:2.78%
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.89%
5
52
182
1818
—
—
—
—
—
5
39
136
1309
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
2.7e-01
4.6e-01
-1.0e+50
—
—
6.7e-01
3.5e-01
cases:15.51%
controls:12.25%
cases:10.16%
controls:6.68%
cases:0.00%
controls:0.80%
—
—
—
—
cases:9.52%
controls:5.13%
cases:17.02%
controls:12.61%
29
229
158
1641
19
125
168
1745
0
15
187
1855
—
—
16
87
152
1609
24
170
117
1178
Labeling mammary gland pathology with ultrasound guidance
HA4AT [2001303990]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
hypromellose
S01KA02 [21605115]
3.5e-02
-1.0e+50
—
—
-1.0e+50
—
4.5e-01
cases:3.21%
controls:3.10%
cases:0.00%
controls:1.55%
—
—
—
—
cases:0.00%
controls:0.32%
—
—
cases:4.26%
controls:2.74%
6
58
181
1812
0
29
187
1841
—
—
0
6
187
1854
—
6
37
135
1311
scopolamine
A04AD01 [21600499]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.88%
—
—
—
—
—
—
—
0
15
168
1681
—
fenoterol and ipratropium bromide
R03AL01 [43534843]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
—
0
6
168
1690
—
Hepatitis A virus IgG Ab [Presence] in Serum by Immunoassay
40724-7 [3040363]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
—
Eye discharge
F03 [2002000401]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.34%
—
0
5
187
1865
—
—
—
—
0
18
141
1330
hydrocortisone and antiinfectives
S02CA03 [21605175]
5.7e-01
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
cases:4.28%
controls:2.46%
cases:0.00%
controls:0.96%
cases:0.00%
controls:0.27%
—
—
—
—
cases:0.00%
controls:0.47%
—
—
8
46
179
1824
0
18
187
1852
0
5
187
1865
—
—
0
8
168
1688
—
Other extensive ultrasound examination of artery
PG1DE [2001309713]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
187
1861
—
—
—
—
—
—
Shoulder lesions
M75 [45557983]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
5
168
1691
—
Fracture of lower end of radius
S52.5 [45573842]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
0
9
168
1687
—
Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection
76080-1 [46235759]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
0
7
168
1689
—
Stenosis and insufficiency of lacrimal passages
H04.5 [45581556]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.29%
—
—
—
—
—
—
—
0
5
168
1691
—
Leukocytes [#/volume] in Urine
30405-5 [3018095]
-1.4e-02
5.8e-01
—
—
—
3.8e-01
3.2e-01
cases:8.02%
controls:8.13%
cases:6.42%
controls:3.69%
—
—
—
—
—
—
cases:4.76%
controls:3.30%
cases:7.80%
controls:5.79%
15
152
172
1718
12
69
175
1801
—
—
—
8
56
160
1640
11
78
130
1270
azelastine; nasal
R01AC03 [21605035]
1.7e-01
—
—
—
—
—
2.9e-01
cases:6.42%
controls:5.45%
—
—
—
—
—
—
—
—
—
—
cases:7.80%
controls:5.93%
12
102
175
1768
—
—
—
—
—
11
80
130
1268
buspirone; oral
N05BE01 [21604601]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
187
1862
—
—
—
—
—
—
Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay
63459-2 [40766189]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
0
6
141
1342
Decompression and freeing of adhesions of peripheral nerve: other or unspecified
ACC59 [2001300650]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
7
187
1863
—
—
—
—
—
0
7
141
1341
Vacuum extractor delivery
O81.4 [45582577]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
6.4e-01
—
—
—
—
—
—
cases:3.21%
controls:1.71%
—
—
—
—
—
—
—
—
—
—
—
—
6
32
181
1838
—
—
—
—
—
—
Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay
5257-1 [3010521]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
141
1343
Mental and behavioural disorders due to use of alcohol, Harmful use
F10.1 [45595844]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
0
10
187
1860
—
—
—
—
—
0
7
141
1341
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
7.4e-01
—
—
—
—
—
6.0e-01
cases:5.35%
controls:2.62%
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:2.37%
10
49
177
1821
—
—
—
—
—
6
32
135
1316
Excessive and frequent menstruation with irregular cycle
N92.1 [45539073]
1.7e+00
-1.0e+50
—
—
—
—
—
cases:3.74%
controls:0.70%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
7
13
180
1857
0
8
187
1862
—
—
—
—
—
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
2.8e-01
2.4e-01
—
—
—
2.3e-01
1.1e-01
cases:17.11%
controls:13.53%
cases:9.09%
controls:7.27%
—
—
—
—
—
—
cases:8.93%
controls:7.19%
cases:15.60%
controls:14.17%
32
253
155
1617
17
136
170
1734
—
—
—
15
122
153
1574
22
191
119
1157
Surveillance of contraceptive drugs
Z30.4 [45547299]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.89%
—
—
—
—
—
—
0
12
141
1336
Dentistry
C5 [903277]
1.0e+00
—
—
—
—
—
1.1e+00
cases:5.35%
controls:2.03%
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:1.48%
10
38
177
1832
—
—
—
—
—
6
20
135
1328
Tumor of uncertain or unknown nature in the ovary without histology
D39.10 [2000501354]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
187
1861
—
—
—
—
—
—
Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma
76348-2 [46235831]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
Flexible bronchoscopy
UGC12 [2001303610]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
187
1863
—
—
—
—
—
—
glucagon; nasal, parenteral
H04AA01 [21602778]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
—
plastic IUD with progestogen; implant
G02BA03 [21602449]
-9.9e-02
—
—
—
-1.0e+50
-1.0e+50
4.0e-01
cases:3.74%
controls:4.12%
—
—
—
—
—
—
cases:0.00%
controls:0.27%
cases:0.00%
controls:0.77%
cases:5.67%
controls:3.86%
7
77
180
1793
—
—
—
0
5
187
1855
0
13
168
1683
8
52
133
1296
Memory disturbance
P20 [2002000816]
—
-1.0e+50
-1.0e+50
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.86%
cases:0.00%
controls:0.37%
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
0
16
187
1854
0
7
187
1863
—
—
0
11
168
1685
—
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
2.7e-01
—
—
—
—
—
—
cases:3.21%
controls:2.46%
—
—
—
—
—
—
—
—
—
—
—
—
6
46
181
1824
—
—
—
—
—
—
Pain, unspecified
R52.9 [45544151]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:1.04%
—
—
—
—
—
—
5
14
136
1334
hydrocortisone
S01BA02 [21603619]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
0
10
187
1860
—
—
—
—
—
Erosion of teeth
K03.2 [45572183]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Other visual disturbances
H53.8 [45586516]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
FEV1
20150-9 [3024653]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.82%
—
—
—
—
—
—
5
11
136
1337
perphenazine; oral, parenteral, rectal
N05AB03 [21604502]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
0
5
187
1865
—
—
—
—
—
0
5
141
1343
FEV1 --post bronchodilation
20155-8 [3023550]
—
-1.0e+50
—
—
—
—
1.7e+00
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.67%
—
0
14
187
1856
—
—
—
—
5
9
136
1339
Polyp of cervix uteri
N84.1 [45567867]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
5.2e-01
—
—
—
—
—
—
cases:2.67%
controls:1.60%
—
—
—
—
—
—
—
—
—
—
—
—
5
30
182
1840
—
—
—
—
—
—
Congestive heart failure
I50.0 [45567179]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.43%
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.74%
0
8
187
1862
0
5
187
1865
—
—
—
—
0
10
141
1338
Laparoscopic sterilisation by constriction of Fallopian tubes
LGA21 [2001306793]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
141
1343
Peak expiratory flow measurement
SPAT1057 [2001700158]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
0
5
141
1343
hydrocortisone
C05AA01 [21601608]
5.0e-01
-3.4e-02
—
—
—
—
-9.1e-02
cases:11.23%
controls:7.11%
cases:3.21%
controls:3.32%
—
—
—
—
—
—
—
—
cases:7.09%
controls:7.72%
21
133
166
1737
6
62
181
1808
—
—
—
—
10
104
131
1244
Blood group antibody investigation [Interpretation] in Plasma or RBC
14575-5 [3019601]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.53%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
187
1860
—
—
—
—
—
—
zolpidem; oral
N05CF02 [21604655]
2.8e-01
—
—
—
-1.0e+50
—
1.9e-01
cases:4.28%
controls:3.26%
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
cases:4.96%
controls:4.15%
8
61
179
1809
—
—
—
0
6
187
1854
—
7
56
134
1292
Limited function/disability (L)
L28 [2002000647]
—
—
—
—
—
—
5.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:2.08%
—
—
—
—
—
—
5
28
136
1320
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
4.5e-01
8.6e-01
—
—
—
6.5e-01
6.9e-01
cases:8.56%
controls:5.61%
cases:4.81%
controls:2.09%
—
—
—
—
—
—
cases:3.57%
controls:1.89%
cases:8.51%
controls:4.45%
16
105
171
1765
9
39
178
1831
—
—
—
6
32
162
1664
12
60
129
1288
hydroxyethylpromethazine, combinations
R06AD55 [21603490]
4.9e-01
—
—
—
—
—
—
cases:2.67%
controls:1.66%
—
—
—
—
—
—
—
—
—
—
—
—
5
31
182
1839
—
—
—
—
—
—
Hypothyroidism, unspecified
E03.9 [45537945]
—
—
—
—
—
—
3.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.26%
controls:3.04%
—
—
—
—
—
—
6
41
135
1307
ebastine; oral
R06AX22 [21603521]
—
3.9e-01
-1.0e+50
—
—
5.0e-01
1.1e-01
—
—
cases:2.67%
controls:1.82%
cases:0.00%
controls:0.32%
—
—
—
—
cases:2.98%
controls:1.83%
cases:3.55%
controls:3.19%
—
5
34
182
1836
0
6
187
1864
—
—
5
31
163
1665
5
43
136
1305
Removal of foreign body from under the skin
SPAT1152 [2001700253]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
3.1e-01
5.6e-01
—
—
—
1.1e+00
6.9e-01
cases:6.95%
controls:5.19%
cases:2.67%
controls:1.55%
—
—
—
—
—
—
cases:3.57%
controls:1.24%
cases:8.51%
controls:4.45%
13
97
174
1773
5
29
182
1841
—
—
—
6
21
162
1675
12
60
129
1288
Trochanteric bursitis
M70.6 [45606304]
—
1.2e+00
—
—
—
1.5e+00
—
—
—
cases:2.67%
controls:0.86%
—
—
—
—
—
—
cases:2.98%
controls:0.65%
—
—
—
5
16
182
1854
—
—
—
5
11
163
1685
—
antiinfectives, combinations
S02AA30 [21605163]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Other blockage of nerve
WX290 [2001310792]
2.4e-01
2.6e-01
-1.0e+50
—
-1.0e+50
—
3.8e-01
cases:11.76%
controls:9.47%
cases:4.81%
controls:3.74%
cases:0.00%
controls:0.37%
—
—
cases:0.00%
controls:0.38%
—
—
cases:13.48%
controls:9.64%
22
177
165
1693
9
70
178
1800
0
7
187
1863
—
0
7
187
1853
—
19
130
122
1218
Acetylcholine receptor Ab [Moles/volume] in Serum
20427-1 [3006257]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.27%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
187
1865
—
—
—
—
—
—
Polyuria
R35 [45539331]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
187
1864
—
—
—
—
—
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
39
174
2.54
5.80
1.3
1.4
—
—
—
0
0
50
261
2.22
5.20
3.0
2.2
94.05
96.61
ug/g
0.05
39
203
88
572
1.96
5.06
2.4
2.3
57.24
62.56
u/l
0.29
79
524
22
83
2.85
4.49
2.8
2.2
—
—
—
0
0
106
757
1.85
4.39
4.6
3.8
37.06
36.34
g/l
0.92
101
717
124
932
1.86
4.33
7.3
5.4
0.53
0.55
e9/l
0.23
114
802
128
974
1.87
4.28
7.2
5.5
0.20
0.18
e9/l
0.95
120
848
126
955
1.86
4.25
7.4
5.5
1.89
2.03
e9/l
0.50
119
847
124
939
1.84
4.16
7.3
5.4
0.04
0.04
e9/l
0.36
114
807
48
269
2.03
4.10
1.4
1.4
170.91
571.25
titre
3.65
11
64
78
529
1.78
3.67
1.9
1.9
114.36
143.64
u/l
0.98
72
507
115
876
1.73
3.55
7.3
5.3
3.18
2.79
%
1.17
108
815
115
878
1.72
3.50
7.3
5.4
8.64
8.50
%
0.24
108
819
115
878
1.72
3.50
7.3
5.4
0.68
0.68
%
0.04
108
813
17
64
2.81
3.49
1.3
1.3
280.90
313.29
ug/g
—
10
35
131
1045
1.73
3.33
9.7
9.7
3.81
3.94
e9/l
0.22
118
909
122
955
1.71
3.32
5.6
5.7
9.44
10.13
umol/l
0.65
112
900
17
67
2.68
3.22
1.6
1.2
—
—
—
0
0
123
975
1.67
3.10
4.2
3.7
55.81
0.00
estimate
0.49
27
205
122
968
1.66
3.04
4.2
3.6
0.00
0.01
estimate
0.50
25
198
124
988
1.67
3.04
4.3
3.7
0.00
0.00
estimate
-0.00
25
185
5
5
10.21
2.99
1.0
1.0
2235.00
2439.60
miu/ml
—
5
5
51
331
1.72
2.69
4.6
3.2
34.95
298.39
ng/l
1.44
38
227
100
783
1.55
2.43
3.4
3.2
6.28
6.22
ph
0.20
52
430
38
234
1.77
2.40
2.1
2.1
20.78
22.65
%
0.49
38
220
52
352
1.64
2.33
2.6
2.6
2.43
2.44
mmol/l
0.48
47
321
68
494
1.57
2.28
1.6
1.3
0.62
2.46
u/ml
1.13
17
128
6
14
4.38
2.16
2.2
2.4
4.32
3.96
nmol/l
—
6
14
8
25
3.29
2.12
1.0
1.2
—
—
—
0
0
5
10
5.10
2.08
1.8
1.5
95.40
83.27
ng/l
—
5
10
98
785
1.48
2.03
2.3
2.0
—
—
—
0
0
78
601
1.49
1.94
7.3
4.8
—
—
—
0
0
23
131
1.85
1.87
1.2
1.4
—
43.35
—
0
13
121
1023
1.46
1.84
3.7
4.2
6.27
6.39
mmol/l
0.29
114
941
30
187
1.71
1.82
3.8
6.9
104.77
104.58
mmol/l
0.10
30
187
90
721
1.45
1.81
3.8
3.4
0.00
0.02
estimate
0.50
17
159
6
18
3.40
1.76
1.3
1.2
—
—
—
0
0
25
150
1.76
1.73
2.8
2.7
7.38
7.39
ph
0.47
12
80
106
883
1.42
1.69
7.1
6.2
1.24
1.22
mmol/l
2.40
93
759
27
167
1.71
1.69
1.1
1.2
—
—
—
0
0
37
254
1.56
1.55
3.3
3.1
2.49
3.67
e6/l
0.30
22
114
33
221
1.59
1.54
1.8
1.9
—
—
—
0
0
38
265
1.54
1.49
1.6
1.6
1096.43
1134.11
nmol/l
0.10
32
195
30
198
1.61
1.48
2.8
2.0
0.00
0.07
estimate
—
7
43
53
398
1.45
1.46
1.4
1.3
22.15
32.72
iu/ml
0.34
13
138
35
241
1.55
1.45
1.3
1.3
—
—
—
0
0
9
39
2.37
1.45
2.7
2.2
61.33
54.53
%
—
9
39
7
29
2.46
1.40
1.1
1.1
—
—
—
0
0
22
136
1.69
1.39
1.2
1.3
—
—
—
0
0
21
129
1.70
1.36
3.0
7.4
—
—
—
0
0
95
798
1.36
1.35
5.7
5.4
1.24
1.22
mmol/l
2.26
85
725
55
422
1.42
1.34
3.1
3.4
1.02
1.02
kg/l
0.13
35
279
26
171
1.60
1.31
4.8
4.0
7.39
7.36
ph
0.88
17
118
57
442
1.40
1.31
1.5
1.4
1.99
2.27
g/l
0.62
37
266
93
784
1.35
1.27
2.5
2.0
98.92
99.00
pmol/l
0.01
53
391
20
125
1.67
1.23
1.8
1.6
1.54
1.49
g/l
0.05
20
115
10
50
2.05
1.18
1.8
1.4
—
—
—
0
0
187
1779
1.73
1.17
17.3
13.3
17.97
19.94
mg/l
0.41
161
1427
0
35
0.00
1.16
0.0
2.1
—
—
—
0
0
12
65
1.90
1.16
2.2
1.8
—
—
—
0
0
35
254
1.46
1.15
1.2
1.2
—
—
—
0
0
97
837
1.31
1.08
2.3
2.5
—
—
estimate
—
0
0
68
559
1.33
1.07
3.0
2.9
—
—
—
0
0
49
383
1.37
1.07
2.8
2.5
7.50
7.97
e6/l
0.05
44
356
89
760
1.31
1.07
13.6
9.6
1.25
1.15
inr
0.92
74
623
5
106
0.46
1.04
1.0
1.1
—
—
—
0
0
159
1474
1.38
1.04
4.6
4.7
14.31
14.65
pmol/l
1.30
148
1369
56
449
1.34
1.04
5.3
4.3
—
—
—
0
0
5
22
2.30
1.04
2.0
1.9
—
—
—
0
0
10
53
1.93
1.03
1.5
2.1
22.81
24.92
mmol/l
—
10
53
0
29
0.00
0.98
0.0
6.2
—
383.38
—
0
24
7
36
1.98
0.98
3.0
1.7
66.71
52.38
%
—
7
36
67
558
1.30
0.95
3.9
3.1
10.92
156.52
e6/l
0.68
56
426
161
1503
1.36
0.94
21.6
17.6
331.47
331.30
g/l
0.08
161
1495
30
221
1.42
0.92
1.3
1.3
—
—
—
0
0
76
646
1.28
0.92
3.6
3.1
2.36
2.36
mmol/l
0.06
71
594
6
28
2.18
0.92
1.3
1.3
7.70
10.73
u/ml
—
6
28
190
1830
1.70
0.91
13.1
12.1
—
—
—
0
0
179
1704
1.46
0.89
6.1
5.7
2.05
1.82
mu/l
2.00
171
1585
10
56
1.83
0.89
1.2
1.1
—
—
—
0
0
13
80
1.67
0.87
2.4
2.5
0.65
0.61
%
0.15
13
80
13
80
1.67
0.87
2.4
2.5
0.98
1.06
%
0.14
13
80
17
113
1.55
0.85
3.0
2.0
0.00
0.03
estimate
—
7
34
6
31
1.96
0.85
2.0
2.3
59.17
59.93
%
—
6
31
91
798
1.26
0.84
11.1
10.2
0.00
0.00
e9/l
0.90
76
645
46
370
1.32
0.84
2.4
1.8
—
—
—
0
0
14
89
1.62
0.83
3.0
2.3
23.09
24.88
mmol/l
1.70
14
89
186
1788
1.54
0.83
6.2
5.7
2.92
2.80
mmol/l
1.20
177
1661
75
646
1.26
0.80
2.6
3.3
11.54
32.68
ng/l
2.28
43
423
64
541
1.27
0.80
4.7
3.5
7.39
7.40
ph
1.28
43
379
8
48
1.69
0.79
1.8
3.2
—
—
—
0
0
0
25
0.00
0.79
0.0
2.2
—
—
—
0
0
51
420
1.29
0.78
2.4
2.5
309.96
321.00
umol/l
0.36
46
370
6
34
1.79
0.77
1.5
1.2
—
—
—
0
0
27
203
1.38
0.76
2.5
2.4
6.41
6.26
umol/l
0.02
22
174
64
545
1.26
0.75
8.3
6.7
—
—
—
0
0
62
529
1.25
0.71
4.1
3.6
0.00
0.01
estimate
0.50
24
182
5
28
1.81
0.66
4.0
2.4
—
—
—
0
0
74
650
1.22
0.65
5.2
4.0
14.05
66.78
e6/l
1.57
58
443
179
1723
1.36
0.63
5.4
4.9
5.71
5.80
mmol/l
0.31
169
1593
66
576
1.22
0.61
2.2
2.1
—
—
—
0
0
28
220
1.32
0.61
1.3
1.4
—
—
—
0
0
0
22
0.00
0.59
0.0
1.4
—
1.45
—
0
22
183
1771
1.37
0.58
5.7
5.0
4.87
4.79
mmol/l
0.58
175
1652
182
1760
1.36
0.58
5.6
4.9
1.51
1.56
mmol/l
0.95
171
1637
6
37
1.64
0.56
7.8
4.2
—
—
—
0
0
48
410
1.22
0.55
3.9
3.8
—
—
—
0
0
9
61
1.50
0.54
1.7
2.1
1.56
1.41
g/l
—
9
56
60
526
1.20
0.53
1.6
1.6
19.70
21.78
nmol/l
0.65
53
436
27
218
1.28
0.50
1.8
1.4
—
—
—
0
0
43
367
1.22
0.50
1.5
1.3
10.88
7.27
u/ml
0.15
22
140
7
46
1.54
0.49
14.6
6.0
—
—
—
0
0
48
550
0.83
0.48
1.4
1.5
—
—
—
0
0
10
142
0.69
0.48
3.3
3.7
1.24
1.23
mmol/l
—
10
119
7
47
1.51
0.48
1.1
1.4
—
—
—
0
0
10
69
1.47
0.45
5.3
3.3
—
—
—
0
0
13
96
1.38
0.42
1.2
2.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
5
34
1.48
0.40
1.0
1.1
—
—
—
0
0
7
104
0.66
0.40
1.0
3.1
—
—
—
0
0
0
18
0.00
0.40
0.0
3.5
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
23
188
1.25
0.39
3.4
4.2
2.98
8.63
ug/l
1.44
18
151
53
474
1.16
0.37
3.8
3.0
0.10
0.48
e6/l
2.16
42
343
16
126
1.29
0.36
1.5
2.5
75.68
69.27
e9/l
0.23
11
96
13
167
0.76
0.36
1.5
1.4
—
—
—
0
0
21
172
1.25
0.36
7.2
5.4
1.94
1.67
ug/l
0.14
21
151
14
109
1.31
0.34
3.1
3.1
0.90
0.74
ug/l
—
8
62
171
1665
1.18
0.32
5.9
5.8
37.72
38.57
mmol/mol
0.93
165
1565
7
99
0.70
0.31
1.1
1.1
—
—
—
0
0
26
222
1.20
0.31
2.1
1.6
—
—
—
0
0
49
541
0.88
0.31
4.5
3.1
13.20
51.17
mg/l
2.98
23
313
7
53
1.33
0.31
2.1
5.5
36.79
36.95
°c
—
7
53
18
149
1.23
0.29
1.2
1.3
94.56
163.31
u/ml
—
9
66
85
800
1.11
0.27
2.1
1.9
1.26
1.33
mmol/l
0.48
72
676
9
75
1.21
0.25
1.3
1.4
—
—
—
0
0
19
161
1.20
0.25
3.6
8.3
7.40
7.42
ph
0.67
11
96
9
77
1.18
0.24
1.3
1.4
—
—
—
0
0
9
77
1.18
0.24
1.3
1.4
—
—
—
0
0
6
81
0.73
0.24
1.2
1.4
—
—
—
0
0
47
430
1.12
0.24
1.9
1.6
0.66
1.06
mg/l
1.71
38
336
12
147
0.80
0.24
4.3
3.5
—
—
—
0
0
5
38
1.32
0.23
3.0
2.3
8.96
7.91
kpa
—
5
38
5
39
1.29
0.23
4.2
2.9
7.58
10.23
pmol/l
—
5
39
59
549
1.11
0.23
3.8
3.1
0.00
0.01
estimate
0.50
18
151
69
733
0.91
0.22
3.1
3.1
—
—
—
0
0
5
41
1.22
0.22
2.6
1.5
293.20
17370.90
e6/l
—
5
29
5
42
1.20
0.21
1.0
1.1
—
—
—
0
0
5
42
1.20
0.21
1.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
91.68
—
0
11
0
11
0.00
0.21
0.0
2.6
—
0.91
—
0
11
0
12
0.00
0.21
0.0
2.8
—
50.83
—
0
6
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
1.6
—
—
—
0
0
0
14
0.00
0.20
0.0
2.9
—
—
—
0
0
6
49
1.23
0.20
2.2
2.0
—
—
—
0
0
11
90
1.24
0.19
2.8
8.5
24.36
24.59
mmol/l
0.12
11
90
7
60
1.17
0.18
5.3
5.1
0.83
0.96
%
—
7
55
52
554
0.92
0.18
4.9
3.8
1.67
9.16
mg/mmol
3.54
24
307
8
68
1.18
0.17
1.0
1.1
1.59
1.63
g/l
—
8
68
16
139
1.16
0.17
1.6
1.4
—
—
—
0
0
8
70
1.15
0.16
1.0
1.1
0.93
0.89
g/l
—
8
70
8
72
1.12
0.16
1.4
1.4
—
—
—
0
0
9
78
1.16
0.15
1.3
1.4
—
—
—
0
0
170
1681
1.07
0.09
4.7
4.1
1.23
1.22
mmol/l
0.02
159
1549
6
54
1.11
0.09
1.2
1.5
32.00
6.39
ug/l
—
6
49
7
66
1.06
0.08
5.3
4.8
1.49
1.59
%
—
7
61
8
78
1.03
0.07
2.1
5.0
—
—
—
0
0
57
587
0.96
0.06
4.1
3.0
6.21
7.21
mmol/l
1.17
49
486
36
345
1.05
0.06
1.8
1.6
—
—
—
0
0
126
1245
1.03
0.05
4.0
3.1
36.67
40.27
u/l
0.48
121
1180
11
118
0.93
0.03
1.6
1.8
—
—
—
0
0
18
187
0.96
0.01
1.3
1.5
—
—
—
0
0
25
243
1.03
0.01
1.5
1.5
—
—
—
0
0
12
126
0.95
0.00
1.0
3.0
68.60
67.24
g/l
0.37
12
117
12
116
1.04
0.00
9.2
5.0
6.91
8.63
mmol/l
0.65
12
110
30
296
1.02
0.00
2.7
2.6
0.83
0.81
mmol/l
0.35
30
280
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
3.7
—
—
—
0
0
9
98
0.91
-0.00
1.1
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
4.8
—
43.94
—
0
9
0
8
0.00
-0.00
0.0
9.3
—
15.08
—
0
8
6
61
0.98
-0.00
1.2
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
10.7
—
8.59
—
0
7
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
201.29
—
0
7

Mortality – FinRegistry

↥

Association

Association between endpoint L12_CHLOASMA and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have L12_CHLOASMA.

N-year risk Females Males
1 No data No data
5 No data No data
10 No data No data
15 No data No data
20 No data No data

Relationships between endpoints

↥

Index endpoint: L12_CHLOASMA – Chloasma

GWS hits: 1

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data